Molecular Partners to Present at Upcoming Healthcare Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm, announced CEO Patrick Amstutz's participation in two investor events in March 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm, announced CEO Patrick Amstutz's participation in two investor events in March 2022. Key dates include the Credit Suisse London Global Healthcare Conference on March 1-2, and a Fireside chat at the Cowen Health Care Conference on March 9. Additionally, the FY 2021 annual report will be published on March 15, followed by an investor conference call on March 16. Webcasted presentations will be accessible via the company's website.
Details
News Market Reaction – MOLN
The recorded move for MOLN in the trading session of this news was +2.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in two upcoming healthcare investor events in March, 2022. In addition, the Company will publish its full year 2021 annual report on March 15 and hold an investor conference call on March 16, 2021.
Presentation Details:
Cowen Health Care Conference – Fireside chat
- Wednesday, March 9, 2022 at 2:10-2:40pm ET
Conference Participation Details:
Credit Suisse London Global Healthcare Conference
- Tuesday, March 1, 2022 to Wednesday, March 2, 2022
Webcasted presentations will be made available through the Molecular Partners website.
| Financial calendar | |
| March 15, 2022 | Publication of FY 2021 Annual report and audited 2021 results |
| April 13, 2022 | Annual General Meeting |
| Conference call details | |
| Date and Time: | March 16, 2021 at 8am ET |
| US/CANADA toll-free dial-in number: | (844) 865-3856 |
| Switzerland dial-in number: | 0800836507 |
| Conference ID: | 5295679 |
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of infectious disease, oncology, and ophthalmology, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
For further details, please contact:
Seth Lewis
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Shai Biran, Ph.D.
shai.biran@molecularpartners.com
Tel: +1 978 254 6286
Thomas Schneckenburger, European IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 79 407 9952
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.